Month: November 2026

Nutriband (NTRB) – Progress Reported Toward Start Of Clinical Trial

Posted on by [email protected]


Monday, November 02, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Commercial Preparations Continue. Nutriband continues to prepare for the AVERSA Fentanyl clinical trial, now expected to begin in 1H27. The NDA will be submitted through the 505(b)(2) pathway and requires a single Phase 1 trial demonstrating abuse deterrence with AVERSA Fentanyl technology.

Opioid Crisis Is Getting Worse. The Opioid Crisis was declared a National Public Health Emergency in October 2017. While overdose deaths have declined from their 2023 peak, the number of people living with opioid addiction has increased. CEO Garth Sheridan recently appeared in a video with Nick Shirley, a well-known YouTuber. The segment featured a walking tour in Los Angeles, speaking with people who live with fentanyl addiction. The segment can be viewed at https://www.youtube.com/watch?v=zyDQOBp4nn4&t=1357s.  


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

NN (NNBR) – Opportunity, Opportunity, Opportunity

Posted on by [email protected]


Monday, November 02, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Opportunity. The biggest takeaway from the quarter is the tremendous amount of opportunity available to NN. The pipeline in the key end markets-Data Center and Electric Grid, Defense and Electronics, and Medical-exceeds $270 million, with an overall pipeline of $750 million, and the prospect list is over $1 billion in additional opportunities being tracked that have yet to be quoted.

Growth. New-business awards totaled $106 million through September, and management expects more than 150 program launches during 2026. Data-center cooling, defense products, and robotic surgery components are expanding NN’s addressable applications. Management raised its full-year awards target to $110 million to $130 million.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

ACCO Brands (ACCO) – Repositioning Ongoing

Posted on by [email protected]


Monday, November 02, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Thoughts on the Quarter. We view the quarter as evidence of progress in cash generation and portfolio repositioning, with an organic earnings recovery still to be demonstrated. Cost actions, school brand performance, and International margin improvement support the operating base. However, acquisitions and currency continue to offset declining comparable sales, and tariff recoveries explain more than the entire quarterly increase in adjusted operating income. A sustained improvement in peripherals sell-through and margins would provide stronger support for a recovery thesis.

Key Quarter Metrics. Back-to-school was a bright spot. Management reported mid-single-digit seasonal growth in the United States and Canada and nearly 20% growth in Mexico. Workspace Solutions segment sales were off low single digits overall, while the Tech Peripherals business was down low double digits.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.